TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15647414
Drug: Didanosine enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine enteric‐coated 400 mg once daily (reference regimen A)
Study: 10227447
Drug: Modified FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FEC regimen (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2 for two courses, followed by a modified third course with a dose of 1200 mg/m2) plus G-CSF (filgrastim) at 5 mg/kg.
Study: 1591822
Drug: Type Ia
Normalized name: MAGNESIUM ALUMINUM SILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type Ia antiarrhythmic agents (quinidine, procainamide, disopyramide)
Study: 1591822
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving type Ia antiarrhythmic agents
Study: 3918450
Drug: Indomethacin rectal
Normalized name: indomethacin Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin rectal suppository (100 mg)
Study: 15985339
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches with counselling
Study: 12640194
Drug: SQV hard-gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV hard-gelatin capsule (HGC)/ritonavir (RTV), 1600/100 mg
Study: 12640194
Drug: SQV soft-gelatin
Normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SQV soft-gelatin capsule (SGC)/ritonavir (RTV), 1600/100 mg
Study: 12640194
Drug: SQV soft-gelatin
Normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SQV soft-gelatin capsules (SGCs)
Study: 12640194
Drug: SQV hard-gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV hard-gelatin capsules (HGCs)
Study: 10759911
Drug: Zolmitriptan, 2.5
Normalized name: Zolmitriptan, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan, 2.5 mg
Study: 10759911
Drug: Sumatriptan, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan, 25 mg
Study: 11135021
Drug: Sumatriptan, 50
Normalized name: Naproxen Sodium-Sumatriptan, 500 mg-85 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan, 50 mg
Study: 28202270
Drug: 25% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% glucose solution
Study: 28202270
Drug: Fructose solution
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose solution
Study: 25305000
Drug: M72/AS01 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01 (1 or 2 doses)
Study: 25305000
Drug: Meningitis vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningitis vaccine or EPI vaccines alone
Study: 1866817
Drug: Chloramphenicol ointment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol ointment and an eye patch for six hours followed by chloramphenicol eyedrops six times a day for six days.
Study: 1866817
Drug: Chloramphenicol ointment
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol ointment and double eye patches for twenty-four hours as the only treatment.
Study: 27111192
Drug: TC‐3 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC‐3 gel + 200 U OnabotA (Group B)
Study: 27111192
Drug: TC‐3 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC‐3 gel + 200 U OnabotA + DMSO (Group C)
Study: 17990225
Drug: Nifurtimox-eflornithine combination
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox-eflornithine combination therapy (eflornithine 400 mg/kg per day IV every 12 h for 7 days + nifurtimox 15 mg/kg per day orally every 8 h for 10 days)
Study: 17990225
Drug: Eflornithine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine alone (400 mg/kg per day IV every 6 h for 14 days)
Study: 12926186
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with Olea europaea extract, administered preseasonally with a maintenance dose 3.8 times higher than conventional treatments, reaching a maximal dose of 75 BU (45 micrograms Ole e 1).
Study: 12926186
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SIT treatment).
Study: 9609132
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day Carbimazole for 12 months (Group 1, n = 23)
Study: 9609132
Drug: 45 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/day for the first month, 30 mg/day for the second, and 20 mg/day for the remaining 10 months of Carbimazole (Group 2, n = 34)
Study: 9815961
Drug: Liposome‐encapsulated muramyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. twice weekly for 8 weeks
Study: 9815961
Drug: Placebo liposomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liposomes (lipid equivalent), twice weekly for 8 weeks
Study: 9815961
Drug: Liposome‐encapsulated muramyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. once or twice weekly for 8 weeks
Study: 9815961
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy (CDDP), 70 mg/m2 i.v. every 21 days x 4
Study: 375153
Drug: promethazine‐A.P.C. combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine‐A.P.C. combination
Study: 23659338
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 supplementation (500 mg/day)
Study: 21805296
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control group (PI without treatment)
Study: 17223420
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention plus intensive, guideline-driven medical therapy
Study: 15378098
Drug: Seated exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seated exercise program (three times per week for four cycles of chemotherapy)
Study: 11469436
Drug: P2 of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2 of 2 msec with d,l-sotalol
Study: 7616557
Drug: Midazolam (Dormicum)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (Dormicum) 7.5 mg
Study: 7616557
Drug: Promethazine (Phenergan)
Normalized name: promethazine Injection [Phenergan]
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Promethazine (Phenergan) 25 mg
Study: 3283661
Drug: Aspirin 1500
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 1500 mg
Study: 18070831
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of temocillin (4 g/day)
Study: 18070831
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily administration of temocillin (2 g every 12 h)
Study: 15101878
Drug: Telephone-based pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based pharmaceutical care program
Study: 15101878
Drug: Routine pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine pharmaceutical care (control)
Study: 3936089
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily cigarette consumption
Study: 31829276
Drug: Real acuTENS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acuTENS treatment for 45 min once a day for five consecutive days
Study: 31829276
Drug: Sham acuTENS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acuTENS treatment for 45 min once a day for five consecutive days
Study: 31829276
Drug: Real acuTENS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acuTENS treatment
Study: 31829276
Drug: Sham acuTENS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acuTENS treatment
Study: 24815889
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 27.5 μg
Study: 22688444
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg (K1)
Study: 22688444
Drug: Ketamine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 3 mg/kg (K2)
Study: 16159570
Drug: Huobahuagen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huobahuagen Tablets (5 tablets po t.i.d.)
Study: 16159570
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 to 300 mg po q.d.)
Study: 8826921
Drug: Leuprolide-flutamide androgen
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprolide-flutamide androgen inhibition therapy
Study: 2147599
Drug: Dichloromethylene bisphosphonate
Normalized name: (dichloromethylene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered orally for 6 months (1600-2400 mg/day)
Study: 2147599
Drug: Dichloromethylene bisphosphonate
Normalized name: (dichloromethylene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by intravenous infusion (500-1000 mg/day)
Study: 2147599
Drug: Dichloromethylene bisphosphonate
Normalized name: (dichloromethylene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by intramuscular injection (100-200 mg/day)
Study: 2147599
Drug: Dichloromethylene bisphosphonate
Normalized name: (dichloromethylene)bisphosphonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by mouth (1600-2400 mg/day)
Study: 6105342
Drug: Propranolol (continuous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (continuous, oral administration, dosage not specified)
Study: 31856425
Drug: atomoxetine 18
Normalized name: atomoxetine 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atomoxetine 18 mg daily
Study: 31856425
Drug: midodrine 5
Normalized name: midodrine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: midodrine 5 mg twice daily
Study: 31856425
Drug: combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination treatment (atomoxetine and midodrine)
Study: 31156144
Drug: Kuan-Sin-Yin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuan-Sin-Yin treatment (Group K)
Study: 31156144
Drug: No Kuan-Sin-Yin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Kuan-Sin-Yin treatment (Group NK)
Study: 28984747
Drug: 30-day diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-day diazepam treatment
Study: 28984747
Drug: 10-day diazepam
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day diazepam treatment
Study: 9608414
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg D-cycloserine
Study: 9608414
Drug: Higher medication
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher medication dosage or long-term treatment
Study: 8080299
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with mitomycin C and/or 5-fluorouracil
Study: 4448416
Drug: Concentrate plus
Normalized name: ASPIRIN 125 g in 1 L / CAFFEINE 37 g in 1 L ORAL LIQUID [AquaSource Aspirin Liquid Concentrate plus Caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate plus heparin
Study: 31102457
Drug: sildenafil (PDE5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil (PDE5 inhibitor) for 8 weeks in mice
Study: 31102457
Drug: sildenafil (PDE5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil (PDE5 inhibitor) for 4 weeks in humans
Study: 25227729
Drug: Concentrated ambient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated ambient coarse PM (CAP) (76.2 ± 51.5 μg/m(3))
Study: 21442804
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Dexamethasone, Methotrexate, Prednisone)
Study: 19635128
Drug: web‐based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: web‐based problem solving through the internet (self‐examination therapy) without a coach
Study: 19635128
Drug: web‐based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: web‐based problem solving through the internet (self‐examination therapy) with the possibility to ask help from a coach on the initiative of the respondent (on demand, by email)
Study: 19635128
Drug: web‐based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: web‐based problem solving through the internet (self‐examination therapy) with weekly scheduled contacts initiated by a coach (once per week, by email)
Study: 19635128
Drug: weekly scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly scheduled contacts initiated by a coach, but no web‐based intervention
Study: 9240732
Drug: Clodronate 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 300 mg
Study: 9240732
Drug: Etidronate 300
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate 300 mg
Study: 9240732
Drug: Clodronate 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 150 mg
Study: 9240732
Drug: Clodronate 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 600 mg
Study: 7901952
Drug: Tandospirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (30 mg)
Study: 31397127
Drug: Moxibustion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion combined with umbilical therapy
Study: 18304907
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg/day, adjustable)
Study: 16996843
Drug: Four IA
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four IA courses at monthly intervals
Study: 12850861
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once a week
Study: 12850861
Drug: Enteric alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric alendronate 70 mg per week
Study: 10369728
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg/day
Study: 10369728
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conjugated estrogens + 1alpha(OH)D3
Study: 7055528
Drug: Buprenorphine 0.6
Normalized name: buprenorphine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.6 mg i.v.
Study: 30223808
Drug: Community-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based care with guardian-administered intramuscular injections
Study: 17028126
Drug: OAC1W (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC1W (1 week of omeprazole, amoxicillin, and clarithromycin)
Study: 17028126
Drug: OAC2W (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC2W (2 weeks of omeprazole, amoxicillin, and clarithromycin)
Study: 17028126
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and amoxicillin (2 weeks)
Study: 8348786
Drug: I2-NaF solution;
Approvals — FDA: no, EMA: no, PMDA: no
Description: I2-NaF solution; administered six times to mothers' dentition.
Study: 8348786
Drug: Placebo solution;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution; administered six times to mothers' dentition.
Study: 7637157
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.15 mg)
Study: 25594352
Drug: rhuFVIIa infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhuFVIIa infusion
Study: 23615461
Drug: R‐CHOP‐14 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐CHOP‐14 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 2 mg, rituximab 375 mg/m² on day 1, oral prednisolone 100 mg on days 1‐5, administered every 14 days for six cycles, followed by two further infusions of rituximab 375 mg/m² on day 1 every 14 days)
Study: 23615461
Drug: R‐CHOP‐21 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐CHOP‐21 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², rituximab 375 mg/m² on day 1, oral prednisolone 40 mg/m² on days 1‐5, administered every 21 days for a total of eight cycles)
Study: 20309699
Drug: Modern drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern drug therapy
Study: 20309699
Drug: Controlled drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled drugs trials
Study: 27197293
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (150 min/wk; n = 44)
Study: 27197293
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (300 min/wk; n = 48)
Study: 20117915
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered on the first surgical visit, followed by placebo on the second visit after 3 weeks.
Study: 20117915
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on the first surgical visit, followed by antibiotics on the second visit after 3 weeks.
Study: 6088439
Drug: Purified concentrated
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified concentrated bran product (FiberformR, 3.5 g) three times daily for 6 weeks
Study: 28612324
Drug: PowerPoint presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PowerPoint presentation (weekly for 4 weeks)
Study: 26852040
Drug: Levofloxacin inhalation
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin inhalation solution (APT-1026) 240mg BID for 28 days
Study: 20669632
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs and targeted therapies for high-risk groups
Study: 20669632
Drug: De-escalated treatment
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalated treatment for better-defined low-risk groups
Study: 20669632
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care (transfusions, antibiotics, pain control)
Study: 18534221
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg per day of PEG3350
Study: 18534221
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg per day of PEG3350
Study: 18534221
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg per day of PEG3350
Study: 11882400
Drug: Early jejunal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early jejunal feeding combined with prophylactic imipenem (Tienam, 500 mg intravenously twice each day)
Study: 11882400
Drug: Conventional parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%; 30 kcal/kg)
Study: 9932944
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug group (low-molecular weight heparinoid)
Study: 7503622
Drug: Nifedipine 40
Normalized name: nifedipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 40 mg/day
Study: 6833654
Drug: Diltiazem 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 270 mg/day
Study: 7503622
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 to 360 mg/day
Study: 7503622
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Verapamil 480 mg/day
Study: 2157737
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (0.25 x 10(4) PFU)
Study: 2157737
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (0.5 x 10(4) PFU)
Study: 2157737
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (10(4) PFU)
Study: 2157737
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (all doses)
Study: 2157737
Drug: Quadrivalent rotavirus
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent rotavirus vaccine (medium and high doses)
Study: 23331949
Drug: ART48 (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART48 (48 weeks antiretroviral therapy)
Study: 23331949
Drug: ART12 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART12 (12 weeks antiretroviral therapy)
Study: 21216164
Drug: Eprinomectin (EPM)
Normalized name: Eprinomectin
DrugBank: Eprinomectin (DB11405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprinomectin (EPM) pour-on preparation at a dose of 0.5 mg/kg bodyweight
Study: 11923161
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days
Study: 9799030
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (N = 14), treated with 1 mg 17beta‐estradiol once daily and 5 or 10 mg dydrogesterone once daily during the third and fourth week of every 4 weeks